3 results
The aim of the study is to evaluate the efficacy of sensor augmented pump (SAP) therapy with MiniMed* 640G and SmartGuard* in preventing hypoglycemic events in comparison with continuous subcutaneous insulin infusion (CSII) therapy in type 1…
1. Overall survival (primary efficacy endpoint)2a. Efficacy: progression-free survival (PFS), overall response rate (ORR = CR + PR), and a clincal benefit rate (CBR) will be evaluated as CR + PR + SD for at least 3 months.2b. Safety: adverse events…
Primary Objective:To compare the efficacy of BMS-986142 versus placebo on a background of MTX as assessed by ACR20 and ACR70 response rates at week 12.Secondary Objectives:1) Assess additional efficacy outcomes of BMS-986142 at week 12 and over 12…